Studieninformationen
Kurztitel:
CC-4047-MM-015
Beschreibung:
Studiendesign:
Phase IV, , Monozentrisch, National
Alter:
>= 18 Jahre
Erkrankungen:
Ein-/Ausschlusskriterien:
Inclusion Criteria: Understand and voluntarily sign an informed consent form, if applicable, and have never been previously treated with pomalidomide before their inclusion in the Registry. Patients with symptomatic, measurable relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both bortezomib and lenalidomide and have demonstrated disease progression on the last therapy and are commencing a pomalidomide based treatment. Exclusion Criteria: Refusal to participate in the Registry or currently participating in the treatment phase of an interventional clinical trial. Pregnancy. Women of childbearing potential, unless all the conditions of the pregnancy prevention program are met. Male patients unable to follow or comply with the required contraceptive measures. Hypersensitivity to the active substance or to any of the excipients.
NCT-Nummer:
Studienaktive Standorte
Praxis Dr. Welslau
Rekrutierung läuft
Herr Dr. Manfred Welslau
m.welslau@onkologie-ab.de